CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肾细胞癌（RCC）每年影响全球逾400,000名患者，其中30%的患者确诊时已出现转移。转移性RCC的现行标准治疗包括酪氨酸激酶抑制剂（TKI）和免疫检查点抑制剂（ICI），也包括联合方案，但临床获益有限。因此亟需新的治疗方法，基于细胞的RCC免疫疗法显示出很大潜力，目前正在临床前研究和早期临床试验中接受评估。本文结合现有疗法综述RCC细胞免疫治疗的研究格局，重点界定当前较理想的抗原靶点、正在探索的细胞治疗产品类型，以及先进工程化策略如何进一步增强RCC细胞疗法。
Renal cell carcinoma (RCC) affects over 400,000 patients globally each year, and 30% of patients present with metastatic disease. Current standard of care therapy for metastatic RCC involve TKIs and ICIs, including combinatorial strategies, but this offers only modest clinical benefit. Novel treatment approaches are warranted, and cell-based immunotherapies for RCC hold significant promise. These are currently being tested in the pre-clinical setting and in early phase clinical trials.
Here, we review the landscape of cellular immunotherapy for RCC in the context of currently available therapies, with a particular focus on defining the current best antigenic targets, the range of cell therapy products being explored in RCC, and how advanced engineering solutions may further enhance these therapies in the RCC space.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
